MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.
Founded in 2020, Leader Life Sciences is a scientific solutions provider dedicated to empowering the research and diagnostic community in the Middle East and North Africa (MENA) region. Serving as a catalyst for innovation, they collaborate with private and public research centers, educational institutions, and healthcare facilities to bring scientific visions to life. Their expertise spans a wide range of domains, including lab automation, digital pathology, turnkey laboratory projects and diagnostics, and beyond. Under this agreement, Leader Life Sciences will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins, immunoassay kits, enzymes, small molecules, proteomic analysis instruments, and spatial biology tools to biopharma companies, laboratories, hospitals, and universities in the GCC region.
"We are excited to partner with Leader Life Sciences to expand the reach of our products and services throughout the GCC countries," said Dr. Peter Schüßler, Vice President and General Manager of Bio-Techne's EMEA region. "Leader Life Sciences' extensive distribution network and industry expertise paired with Bio-Techne's innovative portfolio is the ideal combination to catalyze advances in science and medicine in the region."
"We are thrilled to partner with Bio-Techne, a global leader in innovative life sciences solutions. This collaboration marks a pivotal step in our mission to empower researchers, scientists, and diagnosticians in the MENA region. Together, we are committed to providing cutting-edge technologies that accelerate discovery and enhance advancements in diagnostics, reinforcing our dedication to driving progress of the scientific community of the region," said Nirmal Kumar, Managing Director at Leader Life Sciences.
For more information about Bio-Techne and its range of products and services, visit our Website.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Bio-Techne Contact:
David Clair, Vice President, Investor Relations & Corporate Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
612-656-4416
Leader Life Sciences Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$75.38 |
Daily Change: | 0.51 0.68 |
Daily Volume: | 538,380 |
Market Cap: | US$11.960B |
November 27, 2024 November 25, 2024 November 18, 2024 November 14, 2024 November 11, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB